Paclitaxel-eluting stents

John Cosgrave, Corbett Simon, Rade Babic, Antonio Colombo

Research output: Contribution to journalArticlepeer-review


Percutaneous coronary intervention and stent implantation is rapidly becoming the most commonly used form of revascularization. The long term results of this procedure are limited by restenosis which is a phenomenon predominantly caused by proliferation of smooth muscle cells. Many devices and pharmaceutical agents have been unsuccessful in preventing this problem. Paclitaxel is an antiproliferative drug that has been extensively studied for the prevention of restenosis. This article will review the trial results of the currently available stent platforms and discuss some of the ongoing studies and future directions for the development of new paclitaxel-eluting stents.

Original languageEnglish
Pages (from-to)229-239
Number of pages11
JournalFuture Cardiology
Issue number2
Publication statusPublished - Feb 2006


  • Major adverse cardiac events
  • Paclitaxel-eluting stent
  • Restenosis
  • Revascularization

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Paclitaxel-eluting stents'. Together they form a unique fingerprint.

Cite this